Sign In
Buy HKMPY
$38.02
-0.98 (-2.51%)
At Close: Jun 03, 2026
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
01:19pm, Monday, 01'st Jun 2026
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio - Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other sta
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
06:51am, Thursday, 23'rd Apr 2026
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
02:27am, Thursday, 23'rd Apr 2026
Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
02:27am, Saturday, 28'th Feb 2026
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
10:57am, Thursday, 26'th Feb 2026
Hikma Pharmaceuticals PLC (HKMPY) Q4 2025 Earnings Call Transcript
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
04:13pm, Monday, 08'th Dec 2025
Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON , Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today a
Hikma Pharmaceuticals: Due a dose of confidence
08:18am, Wednesday, 12'th Nov 2025
After a rough six months in which its shares have shed a quarter of their value, Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) looks ready for a rebound. Panmure Liberum thinks the sell-off is overd
Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript
02:26pm, Saturday, 08'th Nov 2025
Hikma Pharmaceuticals PLC (OTCPK:HKMPY) Shareholder/Analyst Call November 6, 2025 4:30 AM EST Company Participants Riad Mishlawi - Interim Head of Injectables Business, CEO & Director Khalid Nabilsi -
Hikma Pharmaceuticals (OTCMKTS:HKMPY) Shares Up 0.9% – Should You Buy?
04:22am, Saturday, 01'st Nov 2025
Hikma Pharmaceuticals PLC (OTCMKTS:HKMPY - Get Free Report) shot up 0.9% on Friday. The stock traded as high as $48.96 and last traded at $48.96. 332 shares changed hands during mid-day trading, a dec
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript
11:37pm, Friday, 08'th Aug 2025
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2025 Pre Recorded Earnings Conference Call August 7, 2025 2:00 AM ET Company Participants Khalid Waleed Hosny Al Nabilsi - Chief Financial Officer Riad Ali M
Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript
09:06am, Friday, 08'th Aug 2025
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2025 Q&A Earnings Call August 7, 2025 4:00 AM ET Company Participants Khalid Waleed Hosny Al Nabilsi - Chief Financial Officer Riad Ali Mishlawi - CEO & Dire
Hikma Pharmaceuticals tumbles after injectables margin outlook cut
04:23am, Thursday, 07'th Aug 2025
Shares of Hikma Pharmaceuticals fell as much as 10% on Thursday after a strong euro prompted the group to lower margin outlook for its injectables unit, despite beating expectations for overall interi
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
08:00am, Wednesday, 02'nd Jul 2025
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON , July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio , June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need fo
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets
